Drugs and Devices

FDA expands use of Xalkori

On March 11, the Food and Drug Administration (FDA) approved Xalkori (crizotinib) to treat people with metastatic non-small cell lung cancer (NSCLC) whose tumors have an ROS-1 gene alteration. Xalkori is the first and only FDA approved treatment for patients with ROS-1 positive NSCLC. Read more


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares